COVID-19 infection in kidney transplant recipients
She is principal investigator of national and international clinical trials dedicated to prophylaxis and treatment of rejection in kidney transplantation. She is actually principal investigator in KTD-Innov and EU-train clinical studies whose goal is to develop and validate innovative tools for early prediction of individual risk prediction for allograft rejection and transplant loss.
Carmen Lefaucheur is involved in the French Speaking Society of Transplantation, in the Banff Conference Scientific Committee and in the Transplantation Society steering committee for guidelines on the treatment of antibody-mediated rejection.
